Genetic testing company Natera (NASDAQ: NTRA) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 34.1% year on year to $794 million. The company’s full-year revenue guidance of $3.02 billion at the midpoint came in 3.8% above analysts’ estimates. Its GAAP loss of $0.42 per share was 56.4% below analysts’ consensus estimates.

Is now the time to buy NTRA? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Natera’s third quarter results were met with a significant negative market reaction despite robust revenue growth and improved operating margins. Management attributed the strong topline performance to higher testing volumes in oncology, organ health, and women’s health, supported by expanded reimbursement coverage and new product launches. Outgoing CEO Steve Chapman cited “exceptional growth in both clinical and pharma product lines,” while incoming CEO Solomon Moshkevich emphasized that “Signatera continues to accelerate, and we were also pleased to see continued growth in women’s health and organ health.” However, increased investment in research and commercial teams, along with higher operating expenses, contributed to a wider than expected net loss, which weighed on sentiment.

Looking ahead, Natera’s updated guidance is driven by continued momentum in its core oncology franchise, expansion into international markets like Japan, and increasing demand for its molecular residual disease (MRD) testing platform among biopharma partners. Management highlighted ongoing investments in early cancer detection studies and the rollout of new product features as key priorities. Moshkevich stated, “We are setting the goal to double revenues in the next three years, reaching $6 billion in revenue in 2029,” while CFO Michael Brophy cautioned that “diagnostics can be a tough business, and there is no rule that ASPs always have to improve in a linear way,” signaling a balanced approach to future growth.

Key insights from management’s remarks

Management pointed to accelerating adoption of MRD testing, diversified growth across business lines, and expanded reimbursement coverage as primary drivers behind the quarter’s performance and raised outlook.

• CEO transition: Steve Chapman stepped down as CEO, handing leadership to Solomon Moshkevich, a long-time executive credited with launching key products like Signatera and Prospera. Chapman will remain as a consultant and advisor to support continuity.
• Oncology and MRD growth: Clinical MRD testing volumes increased 56% year over year, with the Signatera platform gaining traction across multiple cancer types. Management cited robust new account openings and strong repeat testing as evidence of broader clinical adoption.
• Women’s and organ health expansion: Women’s health posted another quarter of mid-to-high single-digit growth, supported by new product features such as Fetal Focus and deep sequencing enhancements. Organ health volumes grew nearly 40%, aided by expanded Medicare coverage for transplant monitoring.
• Pharma and data partnerships: Biopharma demand for MRD technology surged, with pharma and data-related revenues up roughly 70% year to date over last year’s total. The company is investing in infrastructure and talent to support increased demand for clinical trials and data services.
• Margin improvement balanced by investment: Gross margin improved to 65%, but management acknowledged that ongoing investment in clinical trials, early cancer detection studies, and commercial expansion, especially in pharma services, continued to drive higher operating expenses.

Drivers of future performance

Natera’s outlook hinges on sustained MRD testing adoption, international expansion, and the scaling of pharma partnerships, balanced against rising R&D and commercial investments.

• MRD platform expansion: Management expects continued growth in Signatera MRD volumes, with expanding clinical guidelines and new coverage decisions, like the recent Medicare approval for liver cancer surveillance, supporting higher average selling prices (ASPs) and broader market penetration.
• International and product diversification: The upcoming launch of Signatera in Japan and the maturation of data in new cancer indications are anticipated to drive additional growth. Management believes that reimbursement in Japan could be accretive to overall ASPs compared to the U.S., while expansion into head and neck and lymphoma cancers is expected to add new patient populations.
• Pharma and data services tailwinds: Investments in pharma and data infrastructure are expected to result in several hundred million dollars in revenue contribution by 2029. However, management cautioned that continued ramp in operating expenses—particularly for clinical trials and early cancer detection studies—may pressure margins in the near term.

Catalysts in upcoming quarters

Looking to upcoming quarters, our analysts will watch (1) the pace and success of Signatera’s launch and reimbursement process in Japan, (2) the outcome and impact of ongoing MolDX reimbursement submissions across multiple cancer types in the U.S., and (3) the level of pharma partnership activity and clinical trial readouts, especially related to early cancer detection. Execution in cost management during this investment cycle will also be closely monitored.

Natera currently trades at $303.50, down from $363.76 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Stocks that trumped tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.